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Abstract. 
 
During wound healing, ﬁbroblasts are re-
cruited from the surrounding tissue to accomplish re-
pair. The requisite migration and proliferation of the
ﬁbroblasts is promoted by growth factors including 
those that activate the epidermal growth factor recep-
tor (EGFR). Counterstimulatory factors in wound ﬂuid 
are postulated to limit this response; among these fac-
tors is the ELR-negative CXC chemokine, interferon 
inducible protein-10 (IP-10). We report here that IP-10 
inhibited EGF- and heparin-binding EGF-like growth 
factor–induced Hs68 human dermal ﬁbroblast motility 
in a dose-dependent manner (to 52% and 44%, respec-
tively, at 50 ng/ml IP-10), whereas IP-10 had no effect 
on either basal or EGFR-mediated mitogenesis (96 
 
6 
 
15% at 50 ng/ml). These data demonstrate for the ﬁrst 
time a counterstimulatory effect of IP-10 on a speciﬁc 
induced ﬁbroblast response, EGFR-mediated motility.
To deﬁne the molecular basis of this negative trans-
modulation of EGFR signaling, we found that IP-10 did 
not adversely impact receptor or immediate postrecep-
tor signaling as determined by tyrosyl phosphorylation 
of EGFR and two major downstream effectors phos-
pholipase C-
 
g
 
 and erk mitogen-activated protein ki-
nases. Morphological studies suggested which biophysi-
cal steps may be affected by demonstrating that IP-10 
treatment resulted in an elongated cell morphology 
reminiscent of failure to detach the uropod; in support 
of this, IP-10 pretreatment inhibited EGF-induced cell 
detachment. These data suggested that calpain activity 
may be involved. The cell permeant agent, calpain in-
hibitor I, limited EGF-induced motility and de-adhe-
sion similarly to IP-10. IP-10 also prevented EGF-
induced calpain activation (reduced by 71 
 
6 
 
7%). That 
this inhibition of EGF-induced calpain activity was
secondary to IP-10 initiating a cAMP-protein kinase
A-calpain cascade is supported by the following evi-
dence: (a) the cell permeant analogue 8-(4-chlorophe-
nylthio)-cAMP (CPT-cAMP) prevented EGF-induced 
calpain activity and motility; (b) other ELR-negative 
CXC chemokines, monokine induced by IFN-
 
g
 
 and 
platelet factor 4 that also generate cAMP, inhibited 
EGF-induced cell migration and calpain activation; and 
(c) the protein kinase A inhibitor Rp-8-Br-cAMPS ab-
rogated IP-10 inhibition of cell migration, cell detach-
ment, and calpain activation. Our ﬁndings provide a 
model by which IP-10 suppresses EGF-induced cell 
motility by inhibiting EGF-induced detachment of the 
trailing edges of motile cells.
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D
 
URING
 
 normal skin wound healing, fibroblasts
are recruited from the surrounding tissue (Hay,
1993). Fibroblasts migrate into the granulation tis-
sue and proliferate to close the wound. This repopulation,
which involves both migratory and proliferative phases, is
regulated by stimulatory and inhibitory cytokines as well
as matrix constituents (Lawrence and Diegelmann, 1994).
Wound healing is a complex and highly orchestrated pro-
cess regulated by these factors. This is best appreciated for
factors that promote healing. Less well-defined are factors
that act late to end wound repair and limit excessive scar-
ring. These signals have been the focus of interventions
targeted at improving wound repair. Much of these efforts
have been ultimately unsuccessful. However, it is the in-
terplay between pro- and counterstimulatory signals that
needs to be understood for rational interventions to be de-
signed.
Growth factors such as those that activate the EGF re-
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ceptor (EGFR),
 
1
 
 including EGF, TGF-
 
a
 
, and heparin-
binding EGF-like growth factor (HB-EGF), are present at
many stages of wound healing and have strong effects on
both cell proliferation and cell migration (Carpenter and
Cohen, 1978; Wells et al., 1998). EGFR-activating ligands
are produced by or released from platelets during the ini-
tial clot, macrophages during the inflammatory phase, and
fibroblasts during the reparative phase (Blotnick et al.,
1994; Pan et al., 1995). That these EGFR ligands are
present during all stages of wound repair suggests that
they play important roles in wound repair (Kiritsy et al.,
1993; Blotnick et al., 1994; Steenfos, 1994). Activation of
EGFR results in cell proliferation and migration as well as
production of extracellular matrix constituents and pro-
cessing enzymes (Gospodarowicz and Mescher, 1977; Car-
penter and Cohen, 1978; Blay and Brown, 1985; Barran-
don and Green, 1987; Colige et al., 1988; Chen et al.,
1994b). All these attributes point to EGFR factors pro-
moting wound healing. In support of this, EGF has been
shown to improve animal models of wound healing (Breu-
ing et al., 1997).
In the search for counterstimulatory factors, select che-
mokines have been investigated. ELR-negative CXC
chemokines, such as interferon inducible protein-10 (IP-
10) and platelet factor 4 (PF4), have been shown to inhibit
endothelial cell proliferation and migration and angiogen-
esis (Luster et al., 1995; Strieter et al., 1995). IP-10 is pro-
duced late in wound healing, becoming evident 4 d after
wounding (Engelhardt et al., 1998). However, IP-10 is a
chemoattractant for monocytes and T lymphocytes. The
effects of IP-10, if any, on dermal fibroblasts during wound
healing are not known, although negative modulatory ef-
fects on other mesenchymal cells, endothelial cells, make
IP-10 an attractive candidate for limiting wound healing.
Cell motility is a biophysical process that is actively con-
trolled by specific, if yet incompletely defined, biochemi-
cal signaling cascades that result in dissociable biophysical
phenomena (Wells et al., 1998). At least two specific bio-
chemical cascades have been shown to be required for
EGFR-mediated cell motility. The first identified, with
phospholipase C-
 
g
 
 (PLC-
 
g
 
) as the immediate postreceptor
effector, leads to cytoskeletal reorganization and possibly
contributes to lamellipod protrusion (Ware et al., 1998).
The second pathway, via the erk mitogen-activated pro-
tein kinases (MAPKs), leads to partial de-adhesion from
substratum (Xie et al., 1998). Recently, cell detachment at
the rear of locomoting cells has been shown to be a rate-
limiting step in fibroblast motility (Huttenlocher et al.,
1997; Palecek et al., 1997). Regulated activation of the
ubiquitous cytosolic protease, calpain, has been demon-
strated to be important for this focal de-adhesion; if
calpain is blocked, the result is an elongated but ultimately
immobile cell (Huttenlocher et al., 1997; Palecek et al.,
1998). We have evidence that this calpain-dependent event
is modulated by EGFR signaling and required for EGFR-
mediated de-adhesion and motility (Glading, A., P. Chang,
D.A. Lauffenburger, and A. Wells, manuscript in prepara-
tion). Thus, there are specific biochemical signals and bio-
physical processes which may be negatively modulated to
limit cell motility.
A counterstimulatory factor would be predicted to in-
terfere with a specific subset of these biophysical pro-
cesses. Therefore, we investigated whether specific pro-
cesses were targeted by the putative counterstimulatory
chemokine IP-10. The foregoing data suggested a testable
model in which IP-10 negatively affects cell detachment at
the rear to prevent cell motility and thereby limit wound
repair. In this paper we report that IP-10 inhibits EGF-
induced cell migration but not proliferation. We find that
only EGFR-induced motility, but not basal motility that is
signaled by adhesion receptors, is diminished by IP-10.
This occurs at a postreceptor level since upstream EGFR
signaling pathways are unaffected by IP-10 exposure.
EGFR-mediated cell de-adhesion and rear detachment
are significantly impaired in the face of IP-10 signaling.
Furthermore, our data suggest that this occurs via a
cAMP-dependent protein kinase A (PKA) attenuation of
calpain activation, as similar biochemical and biophysical
readouts can be mimicked by directly modulating these
biochemical signals and mediators.
 
Materials and Methods
 
Reagents
 
Hs68 normal human diploid fibroblasts were purchased from American
Type Culture Collection. Hs68 cells were used at passage 5–12. IP-10,
monokine induced by IFN-
 
g
 
 (MIG), and PF4 were purchased from Pep-
rotech. EGF was obtained from Collaborative Biomedical Products.
HB-EGF and 8-(4-chlorophenylthio)-cAMP (CPT-cAMP) was purchased
from Sigma Chemical Co. Calpain inhibitor I was purchased from Biomol.
PDGF-BB, Rp-8-Br-cAMPS, and Rp-8-Br-cGMPS were purchased from
Calbiochem. Plastic dishes for cell culture were purchased from Becton
Dickinson.
 
In Vitro Wound Healing Assay
 
EGF-induced migration was assessed by the ability of the cells to move
into an acellular area (Chen et al., 1994b). Hs68 cells were plated on
6-well plastic dishes and grown to confluence in DME with 10% FBS. Af-
ter 48 h quiescent in the media with 0.1% dialyzed FBS, an area was de-
nuded by a rubber policeman at the center of the plate. The cells were
then treated with or without chemokines and EGF (1 nM) and incubated
at 37
 
8
 
C. Photographs were taken at 0 h and 24 h, and the relative distance
traveled by the cells at the acellular front was determined.
 
Cell Proliferation Assay
 
EGF-induced proliferation was determined by the incorporation of
[
 
3
 
H]thymidine (Chen et al., 1996). Cells were grown to confluence in 12-
well plates and quiesced for 48 h in DME with 0.1% dialyzed FBS and
then incubated with the indicated concentration of IP-10 and EGF (1 nM)
for 16 h. [
 
3
 
H]Thymidine (5 
 
m
 
Ci/well) was added, and cells were incubated
for a further 10 h. Cells were treated with 5% trichloroacetic acid for 30
min at 4
 
8
 
C and incorporated label solubilized by 1 N NaOH. Samples
were analyzed by liquid scintillation counter (Beckman Fullerton).
 
cAMP Assay
 
Cells were plated in 10-cm culture plates and grown to confluence in
DME with 10% FBS. Following the treatment of IP-10 for 2 or 4 h, ice
cold extraction buffer (50% ethanol, 0.1 N HCl) were added and incu-
bated on ice for 15 min. Extracts were lyophilized and resuspended in 100
 
m
 
l of water. cAMP was quantitated using a cAMP assay kit (Amersham
 
1. 
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g
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g
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Life Science Inc.). After the extraction cells were lysed with 0.1 N NaOH
and analyzed for protein content by Bradford protein assay.
 
Immunoblotting and Immunoprecipitation
 
Activation of EGFR, PLC-
 
g
 
, and the erk MAPK were assessed by their
tyrosyl-phosphorylation by immunoprecipitation and immunoblotting.
Cells were treated with IP-10 (50 ng/ml) before EGF (1 nM) treatment.
Cell lysates were separated on 7.5% SDS-PAGE and transferred to a
PVDF membrane Immobilon-P (Millipore). Blots were probed by anti–
phospho-erk-MAPK (New England Biolabs) or anti–calpain I or –calpain
II (Biomol) antibodies before visualizing with AP-conjugated second-
ary  antibodies followed by development with a colorimetric method
(Promega).
For immunoprecipitations, cells (2 
 
3
 
 10
 
7
 
) were treated with IP-10 and
EGF as described above. Cell lysates were incubated overnight at 4
 
8
 
C
with the indicated antibody, mixed monoclonal anti–PLC-
 
g
 
1 (Upstate
Biotechnology Inc.) or monoclonal anti-EGFR (Oncogene Science). Im-
munocomplexes were incubated with protein G–agarose and centrifuged.
The pellets were washed three times with 20 nM Hepes buffer (pH 7.4)
containing 10% glycerol, 0.1% Triton X-100, 500 mM sodium chloride, 1
mM sodium vanadate. Precipitated proteins were size-fractionated by
SDS-PAGE and transferred to a PVDF membrane. Tyrosyl phosphoryla-
tion was determined by immunoblotting using the anti–phospho-tyrosine
PY-20 (Transduction Laboratories). By diluting test specimens, we empir-
ically found that we could detect difference in the signal strength on the
order of 10%.
 
Morphological Analysis
 
Cells were plated in 2 ml in 6-well tissue culture plates with DME contain-
ing 0.1% dialyzed FBS at the concentration of 10
 
5
 
 cells/ml. After 12 h of
incubation at 37
 
8
 
C cells were treated with EGF (1 nM) and IP-10 (50 ng/
ml) for another 24 h at 37
 
8
 
C. Cells were visualized by phase-contrast mi-
croscopy. Cell perimeter and cell surface area were analyzed by manually
tracking cell edges on the computer-captured phase-contrast image using
DIAS Dynamic image analyzing system (Solltech) and are expressed as a
ratio of arbitrary units. Asymmetry index of nucleus localization was ob-
tained by measuring the greatest cell length and the length between the
nuclei and the tip of the longest projection, and calculating the deviation
from equidistance (nucleus localization varies from central, a fraction of
0.5 and an index of 0, and at tip of a projection, for a fraction of 1.0 or an
index of 100).
 
Adhesion Assay
 
Cell-substratum adhesiveness was quantitated using inverted centrifuga-
tion detachment. 24-well plates were coated with the human extracellular
matrix Amgel (0.5 
 
m
 
g/ml) (Siegal et al., 1993) for 1 h at room temperature,
after which they were blocked with 1% BSA for 60 min at room tempera-
ture. The plates were washed twice with PBS and used for the following
experiment. Cells were plated at the concentration of 10
 
5
 
 cells/ml with
quiescent media (0.1% FBS) into Amgel coated plates and incubated for
12 h at 37
 
8
 
C. Plates were filled with DME with 1% BSA and 25 mM
Hepes. Then plates were sealed with ELISA sealing tape (Corning) and
centrifuged inverted for 5 min at 4,000 rpm at 37
 
8
 
C using Beckman CS6R
plate centrifuge; 4,000 rpm (2,920 
 
g
 
) was chosen empirically as the force
required to detach approximately half of EGF-treated cells. Before and
after centrifugation, the amounts of cells on the plates were counted by
phase-contrast microscopy.
 
Calpain Activity Assay
 
Cells were grown to confluence in 10-cm tissue culture plates and quiesced
in DME with 0.1% dialyzed FBS for 48 h. After 4 h of treatment of IP-10
(50 ng/ml) with or without Rp-8-Br-cAMPS (50 
 
m
 
M), cells were treated
with EGF (1 nM) and/or CPT-cAMP (20 
 
m
 
M) for 30 min. Cells were
washed twice with ice cold PBS and lysed with cell lysis buffer (20 nM
Hepes, pH 7.4, 10% glycerol, 0.1% Triton X-100, 500 mM sodium chlo-
ride, 1 mM sodium vanadate). After removing the cell debris by centrif-
ugation, dichlorotriazinylamino-fluorescein–labeled microtubule-associ-
ated protein 2 (MAP2) (Cytoskeleton) (50 
 
m
 
g/ml) (Tompa et al., 1995)
was added to the samples with either 0 or 10 mM free Ca
 
2
 
1
 
 concentration
and incubated for 3 min at 30
 
8
 
C. Samples were measured by Aminco-
Bowman Series II spectrofluorometer (Spectronic Instruments Inc.) at ex-
citation and emission wavelengths of 490 and 520 nm, respectively.
Levels of calpain I, calpain II, and calpastatin were assessed by immu-
noblotting using specific antibodies (Biomol).
 
Results
 
IP-10 Inhibits EGFR-mediated Cell Migration but
Not Proliferation
 
To determine whether the putative counterregulatory ELR-
negative CXC chemokine IP-10 affects fibroblast func-
tioning and responsiveness, we examined EGF-induced
proliferation and migration in the presence of IP-10. Basal
and EGF (1 nM)-induced cell migrative capacities were
452 
 
6 
 
10 and 703 
 
6 
 
26 
 
m
 
m/d, respectively. IP-10 was seen
to inhibit EGF-induced cell migration (Fig. 1 a). IP-10 at 1
ng/ml had no effect, but 10 ng/ml and 50 ng/ml inhibited 1
nM EGF-induced cell migration 46% and 48%, respec-
tively. This is not overcome by supersaturating doses of
EGF, as IP-10 also inhibits 10 nM EGF-induced cell mi-
gration 43% (10 ng/ml) to 45% (50 ng/ml). On the other
hand, no significant difference was found in basal cell mi-
grative capacities which is signaled via adhesion receptors.
These data suggest that IP-10 disrupts EGFR-mediated
modulatory signals rather than the motility process per se.
IP-10 may diminish either EGFR signaling or specifi-
cally interrupt motility-enhancing pathways. To determine
whether there was global abrogation of EGFR signaling,
the effect of IP-10 on EGF-induced proliferation was ex-
amined (Fig. 1 b). The presence of IP-10 diminished nei-
ther basal nor EGF-induced thymidine incorporation
suggesting that IP-10 modulatory signals target motility-
specific pathways.
To ascertain whether IP-10 affected EGF as a ligand
rather than EGFR-mediated signals, we tested the cell re-
sponse to HB-EGF. HB-EGF–induced cell migration was
also found to be inhibited up to 47% by IP-10 (Fig. 1 a).
This was not unexpected as the pleiotropic nature of re-
sultant cellular responses to EGF is thought to be due to
intracellular signaling rather than multiple signals encoded
in the ligand. Thus, these initial investigations pointed to a
specific attenuation of the EGFR-mediated motility re-
sponse.
 
IP-10 Does Not Inhibit EGFR, PLC-
 
g
 
, or
MAPK Phosphorylation
 
The fact that IP-10 blocks EGFR-mediated motility but
not proliferation suggested that the point of signal disrup-
tion lies downstream of the receptor. This was confirmed
by finding that IP-10 pretreatment had no effect on ligand
activation of EGFR kinase as determined by whole cell ty-
rosyl-phosphorylation profiles in response to EGF (Fig. 2
a) (Chen et al., 1996). Even after 5 h of IP-10 exposure
EGFR kinase was unaffected (data not shown).
Two divergent pathways have been shown to be re-
quired for EGFR-mediated motility, those involving PLC-
 
g
 
(Chen et al., 1994b) and the erk family of MAPK (Xie et al.,
1998). Therefore, we examined if the activation state of
these mediators was adversely affected by IP-10 (Fig. 2, b
and c). Neither the basal nor the EGF-stimulated tyrosyl-
phosphorylation of PLC-
 
g
 
, nor dual phosphorylation of
erk MAPK was diminished after either 10 min or 5 h of
IP-10 exposure. These findings confirmed that IP-10 did 
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not adversely impinge on EGFR signaling at the receptor
or proximal postreceptor level.
 
IP-10 Exposure Results in an Elongated
Cell Morphology
 
In the absence of effects on these signaling pathways, the
target of signal attenuation is predicted to be downstream,
and at or near the rate-limiting biophysical steps for motil-
ity. As an initial attempt to identify the affected biophysi-
cal process, cells were examined in the presence and
absence of chemokine (Fig. 3). EGF-treated Hs68 cells
presented a motile fusiform shape compared with control
cells. IP-10 pretreatment prevented this conversion to a
more contracted cell with shorter forward and rear projec-
tions. To determine if these morphological changes were
significantly affected, two ratios were determined: extent
of cell contraction and asymmetry of nuclear localization
(Table I). Comparing the cell perimeter to surface contact
area demonstrated that EGF-treated cells were signifi-
cantly compacted compared with untreated cells, whereas
IP-10 prevented this morphological change (
 
P
 
 
 
, 
 
0.01),
while not affecting basal cell morphometry. As this ratio
may simply reflect centripetal contraction rather than mo-
tility-related changes, we also determined the asymmetry
index of the nucleus localization; this should remain un-
Figure 1. Effects of IP-10 on
EGF-induced cell migration (a)
and cell proliferation (b). Cells
were grown to confluence and
quiesced for 48 h in DME with
0.1% dialyzed FBS before treat-
ment with or without IP-10
(1–50 ng/ml), EGF (1–10 nM),
and/or HB-EGF (1 nM). Cell
migration (a) and cell prolifera-
tion (b) assays were performed
as described in Materials and
Methods. The data are shown as
the ratio to the 1 nM EGF-
induced cell migrative or cell
proliferative activity. The data
are the mean 6 SEM of at least
three independent studies each
performed in triplicate. Statisti-
cal analyses were performed by
Student’s  t test as compared
with EGF- or HB-EGF–induced
cell migrative or cell prolifera-
tive capacity in the absence of
IP-10: *P , 0.05, **P , 0.01.
Figure 2. Tyrosine phosphory-
lation induced by EGF stimu-
lation. Cells were grown to
confluence and quiesced with
the DME containing 0.1% dia-
lyzed FBS for 48 h. (a and b)
Cells then were treated with
IP-10 (50 ng/ml) for 10 min be-
fore the 5 min of EGF (1 nM)
stimulation. Cells were then
lysed, and equal volumes of
proteins were analyzed for
phospho-tyrosine (a) and
phospho-erk-MAPK (b) by im-
munoblotting. (c) For PLC-g
analyses, cells were treated
with IP-10 (50 ng/ml) for 10
min or 5 h before the 5 min of
EGF (1 nM) treatment. Cell ly-
sates containing same amounts
of proteins were immunopre-
cipitated with anti–PLC-g anti-
body. Then immunoprecipitates were analyzed by 7.5% SDS-PAGE and immunoblotted with anti–phospho-tyrosine antibody
PY-20. Representative blots of three independent experiments are shown. 
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changed and central during retraction but be offset during
locomotion. Again, EGF treatment resulted in a motile
morphology which was abrogated by IP-10 pretreatment
(
 
P
 
 
 
, 
 
0.01). Thus, IP-10 inhibits EGF-induced cell compac-
tion and results in elongated cell morphology, a phenotype
reminiscent of cells that are unable to detach from substra-
tum (Huttenlocher et al., 1997; Palecek et al., 1997).
 
IP-10 Inhibits EGF-induced Cell Detachment and Cell 
Migration by Inhibiting Calpain Activation
 
Morphological analyses suggested that EGF-induced cell
detachment from substratum is inhibited by IP-10 signal-
ing. Therefore, we assessed the effect of IP-10 on cell ad-
hesion to the human extracellular matrix Amgel by the
centrifugation detachment method. Subjecting the cells to
2,920 
 
g
 
 for 5 min resulted in negligible removal of non-
treated control Hs68 cells (84 
 
6 
 
3% remaining) but about
half of the EGF-treated cells (53 
 
6 
 
4% remaining) (Fig.
4). IP-10 by itself slightly diminished cell adhesiveness (80 
 
6
 
3% remaining), but significantly diminished EGF-induced
detachment (77 
 
6 
 
2% remaining,
 
 P 
 
, 
 
0.01 vs. EGF treat-
ment).
According to the morphological and cell detachment
analyses, we predicted that EGF-induced focal adhesion
disassembly and cell de-adhesion (Xie et al., 1998) are af-
fected by IP-10. Therefore, we focused on biochemical
events which affect focal adhesion disassembly, with
calpain being a prime candidate due to its recent associa-
tion with adhesion disruption and reorganization (Hutten-
locher et al., 1997; Stewart et al., 1998). In addition, an an-
cillary study in our lab has found that EGF induces calpain
activity in fibroblasts and that this is required for cell de-
adhesion from substratum (Glading, A., P. Chang, D.A.
Lauffenburger, and A. Wells, manuscript in preparation).
In agreement with the hypothesis that calpain modulation
leads to de-adhesion, the pharmacological inhibitor, cal-
pain inhibitor I, also prevented EGF-induced detachment
by 68% (74 
 
6 
 
3% remaining). That this is linked to cell
motility is shown by the fact that calpain inhibitor I also di-
minished EGF-induced, but not basal, motility (Fig. 5). In-
terestingly, this partial inhibition of EGF-induced cell mo-
tility would be expected from the report that de-adhesion
of the trailing edge of cells is rate limiting only on highly
adhesive surfaces (Palecek et al., 1997); thus, on a mixed
substratum such as the one used, Amgel, one might pre-
dict only a partial effect of diminishing de-adhesion.
Figure 3. Morphology of EGF-
and IP-10–treated cells. Cells
were plated in 6-well tissue cul-
ture plates with DME containing
0.1% dialyzed FBS at the con-
centration of 105 cells/ml. After
12 h of incubation, cells were
treated with EGF (1 nM) and IP-
10 (50 ng/ml) for another 12 h,
after which pictures were taken
by phase-contrast microscopy.
Pictures were representative
fields from three independent
experiments.
 
Table I. Hs68 Cellular Morphometry
 
Treatment Perimeter vs. area Trend line Asymmetry index
 
No tx 3.66 
 
6
 
 0.13 3.7223 18 
 
6
 
 2
EGF 4.19 
 
6
 
 0.14* 4.6448 30 
 
6
 
 2*
IP-10 3.51 
 
6
 
 0.12 3.7940 21 
 
6
 
 2
IP-10 
 
1
 
 EGF 3.62 
 
6
 
 0.13 3.6033 20 
 
6
 
 2
 
Cells were plated at the concentration of 10
 
5
 
 cell/ml and incubated in quiescent media
for 24 h. Cells were treated with EGF (1 nM) and IP-10 (50 ng/ml) for 12 h. Phase-
contrast images were captured at 0 and 12 h for image analysis. Perimeter and cell sur-
face area were measured by manually tracking cell edges using DIAS image analyzing
system (Solltech). Asymmetry indices were calculated as described in Materials and
Methods. The data are the mean 
 
6
 
 SEM (
 
n
 
 
 
5
 
 100 cells from two experiments each
analyzing 40–60 cells): *
 
P
 
 
 
,
 
 0.01 compared to the other three conditions. 
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A major question is how this inhibition may be signaled.
IP-10 is a member of the subfamily of ELR-negative CXC
chemokines which bind to and activate the CXCR3 recep-
tor, leading to an increase in cAMP levels (Loetscher et al.,
1996; Farber, 1997). Therefore, we asked if this was the
operative second messenger. We determined that IP-10 in-
duced a slow rise of total cellular cAMP level up to ap-
proximately twofold at 4 h (1.97 
 
6 
 
0.53-fold;
 
 P 
 
, 
 
0.05), a
response consistent with published reports on hematopoi-
etic cells (Aronica et al., 1995). Thus, if cAMP was the ini-
tial second messenger, then a cAMP analogue, the cell
permeable CPT-cAMP, should mimic the effects of IP-10.
Similar to IP-10 itself, CPT-cAMP inhibits EGF-induced
cell migration 
 
z
 
50%, but not basal cell motility (Fig. 5).
Another membrane permeant cAMP analogue, dibutyryl-
cAMP, and the cAMP-generating agonist, forskolin, also
reduced EGF-induced motility by about half (data not
shown).
 
IP-10 Inhibits Calpain Activation and Cell Motility 
through cAMP-PKA-Calpain Signaling Pathway
 
In parallel to its effect on EGF-induced cell adhesiveness
and motility, IP-10 significantly inhibited EGF-induced
calpain activity (by 71 
 
6 
 
7%) (Fig. 6 a). If calpain activa-
tion was the point of signal convergence, then cAMP
should also reduce calpain activity and de-adhesion. EGF-
induced calpain activation in cells treated with CPT-
cAMP was inhibited by 99 
 
6 
 
2%. This decreased calpain
activity was due to prevention of enzymatic activation and
not a change in cellular levels of the calpain system as
Figure 4. The effects of IP-10 and calpain inhibitor I on EGF-
induced cell detachment. Cells were plated into the 24-well Am-
gel coated plates with quiescent media and incubated for 12 h.
After pretreatment with or without IP-10 (50 ng/ml for 4 h) or
calpain inhibitor I (1 ng/ml for 30 min), cells were treated with or
without EGF (1 nM) for 30 min. Before and after the centrifuga-
tion, the numbers of the cells on the plates were counted under
the phase-contrast microscope observation. The data are the
mean  6 SEM of three independent studies each performed in at
least 18 wells. Statistical analyses were performed by Student’s t
test.
Figure 5. The effects of calpain inhibitor I and CPT-cAMP on
cell migration. Cells were grown to confluence and quiesced for
48 h in DME with 0.1% dialyzed FBS before treatment with or
without IP-10 (1–50 ng/ml), EGF (1–10 nM), calpain inhibitor I
(1 ng/ml), and/or CPT-cAMP (10 mM). Cell migration assays
were performed as described in Materials and Methods. The data
are shown as the ratio to the 1 nM EGF-induced cell migrative
activity. The data are the mean 6 SEM of at least three indepen-
dent studies each performed in triplicate. Statistical analyses
were performed by Student’s t test.
Figure 6. EGF-induced calpain activation. (a) Cells were grown
to confluence in 10-cm tissue culture plates and quiesced for 48 h
with DME containing 0.1% dialyzed FBS. Cells were treated
with IP-10 (50 ng/ml) for 4 h or CPT-cAMP (20 mM) for 30 min
before EGF (1 nM) for 30 min. Calpain activities were analyzed
by measuring the elevation in fluorescence intensity that occurs
upon calpainolytic digestion of dichlorotriazinylamino-fluores-
cein–labeled MAP2. The data are shown as a ratio to EGF-
induced calpain activation. The data are the mean 6 SEM of at
least three independent studies. Statistical analyses were per-
formed by Student’s t test. (b) Cells were grown to confluence in
6-well tissue culture plates and quiesced for 48 h. Cells were
treated with IP-10 (50 ng/ml) for 4 h before EGF (1 nM) for 30
min. Cell lysates were separated by SDS-PAGE, transferred to
Immobilon-P (Millipore), and immunoblotted with an anti–
calpain I or –calpain II antibody (Biomol). 
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shown by relatively constant cellular levels of the calpains
(Fig. 6 b) in the face of IP-10 treatment.
The above data suggested that IP-10 inhibits EGF-
induced cell migration by inhibiting calpain activation
through cAMP signaling. To determine whether cAMP-
dependent PKA is involved in this IP-10 calpain signaling
pathway, cell migration was performed in the presence of
the cell permeant PKA inhibitor Rp-8-Br-cAMPS; the
protein kinase G preferential inhibitor Rp-8-Br-cGMPS
was used as a control. Rp-8-Br-cAMPS abrogated IP-10’s
inhibitory effect by 87%, but Rp-8-Br-cGMPS did not
(Fig. 7 a). Rp-8-Br-cAMPS, but not Rp-8-Br-cGMPS, also
prevented IP-10 from inhibiting EGF-induced detachment
(Fig. 7 b). In support of our model that calpain activation
is central to IP-10 inhibition of EGFR-mediated motility,
the PKA preferential Rp-8-Br-cAMPS, but not the pro-
tein kinase G preferential inhibitor, abrogated the ability
of IP-10 treatment to inhibit calpain activation almost
completely (Fig. 7 c). In a parallel study, NR6 fibroblasts
expressing full-length EGFR were stimulated to migrate
in the presence of CPT-cAMP; time lapse videomicros-
copy revealed that they were retarded in the ability to re-
tract the trailing edge (data not shown), a cell behavior
similar to that noted with IP-10 (Fig. 3).
 
Other ELR-negative CXC Chemokines Also Increase 
Total Cellular cAMP Level and Inhibit EGF-induced 
Cell Migration by Inhibiting EGF-induced
Calpain Activation
 
One of the predictions from our model of chemokine neg-
ative crossmodulation of growth factor receptor–mediated
motility is that other chemokines that similarly lead to
cAMP generation also would preferentially inhibit EGF-
induced motility. The effects of two other ELR-negative
CXC chemokines, MIG and PF4, were determined. These
chemokines induced slow accumulation of intracellular
cAMP (at 4 h: MIG, 1.92 
 
6 
 
0.38-fold; PF4, 2.13 
 
6 
 
0.49-
fold) that was indistinguishable from IP-10. Both MIG (49 
 
6
 
4% inhibition) and PF4 (45 
 
6 
 
10% inhibition) inhibited
EGF-induced, but not basal motility (Fig. 8 a), and had lit-
tle effect on thymidine incorporation (data not shown). As
per the proposed model, both MIG and PF4 inhibited
EGF-induced calpain activity (Fig. 8 b).
A second prediction would be that IP-10 would prevent
motility induced by other growth factors. We examined
PDGF-induced motility of the Hs68 cells. Similar to its
effect on EGF-induced motility, IP-10 partially blocked
PDGF-induced motility by 46 
 
6 11% (Fig. 8 c). That this
Figure 7. The effects of PKA inhibitor on IP-10 inhibition of EGF-induced cell migration (a), cell detachment (b), and calpain activa-
tion (c). (a) Cells were grown to confluence and quiesced for 48 h before treatment with or without IP-10 (50 ng/ml), Rp-8-Br-cAMPS
(50 mM), Rp-8-Br-cGMPS (50 mM), and/or EGF (1 nM). Cell migration assays were performed as described in Materials and Methods.
The data are shown as the ratio to the 1 nM EGF-induced cell migrative activity. The data are the mean 6 SEM of more than three in-
dependent studies each performed in triplicate. Statistical analyses were performed by Student’s t test. (b) Cells were plated into the 24-
well Amgel coated plates with quiescent media and incubated for 12 h. After pretreatment with or without IP-10 (50 ng/ml), Rp-8-Br-
cAMPS (50 mM), and/or Rp-8-Br-cGMPS (50 mM) for 4 h, cells were treated with or without EGF (1 nM) for 30 min. Before and after
centrifugation, the numbers of the cells on the plates were counted under the phase-contrast microscope observation. The data are the
mean 6 SEM of three independent studies each performed in at least 18 wells. Statistical analyses were performed by Student’s t test.
(c) Cells were grown to confluence in 10-cm tissue culture plates and quiesced for 48 h. Cells were treated with or without IP-10 (50 ng/
ml), Rp-8-Br-cAMPS (50 mM), and/or Rp-8-Br-cGMPS (50 mM) for 4 h before EGF (1 nM) for 30 min. Calpain activities were analyzed
by measuring the elevation in fluorescence intensity that occurs upon calpainolytic digestion of dichlorotriazinylamino-fluorescein–
labeled MAP2. The data are shown as a ratio to EGF-induced calpain activation. The data are the mean 6 SEM of at least three in-
dependent studies. Statistical analyses were performed by Student’s t test.The Journal of Cell Biology, Volume 146, 1999 250
is accomplished through the same signaling pathway as
that which inhibits EGF-induced motility is demonstrated
by IP-10 inhibition of PDGF-induced motility also being
abrogated by Rp-8-Br-cAMPS (Fig. 8 c). These findings
support the model that growth factor–induced motility de-
pends, at least in part, on a calpain-mediated de-adhesion
step which may be negatively impacted by chemokine gen-
eration of cAMP.
Discussion
We present here evidence that the counterstimulatory
chemokine IP-10 affects dermal fibroblast cell responses
to growth factors in addition to its known actions on he-
matopoietic and endothelial cells. We demonstrated that
IP-10 inhibits EGFR-mediated motility specifically, likely
via a cAMP/PKA-dependent inhibition of EGFR-medi-
ated calpain activation. To our knowledge, this is the first
report of the inhibitory effects of IP-10 on growth factor–
induced fibroblast motility. These actions implicate a role
for IP-10 in limiting fibroblast infiltration during wound
healing in response to locally expressed growth factors.
We determined that IP-10 did not disrupt EGFR signal-
ing at the ligand or receptor level. This was expected as (a)
both EGF- and HB-EGF–induced motility was similarly
inhibited; and (b) EGFR-mediated proliferation was unaf-
fected by IP-10 pretreatment. As cellular response signal-
ing diverges at the immediate postreceptor level with at
least one pathway, via PLC-g, being required for motility
but not proliferation (Chen et al., 1994a,b, 1996), it was
reasonable to investigate whether IP-10 differentially ab-
rogated signaling through the PLC-g pathway. The activa-
tion status of this pathway and a second pathway required
for both motility and mitogenesis, through erk MAPK, as
mirrored by tyrosyl-phosphorylation, was investigated and
found to be unaffected by IP-10 treatment. As the links
between these and other postreceptor pathways and the
biophysical events which actuate motility are still in-
completely deciphered (Wells et al., 1998), the affected
biophysical process was approached by morphometric
analyses. IP-10 inhibited EGF-induced cell retraction and
resulted in an elongated cell morphology reminiscent of
failure to detach to the uropod. Rear detachment is neces-
sary for migration (Chen, 1981; Huttenlocher et al., 1997;
Palecek et al., 1998). Taken together with our previous
finding that EGF induces focal adhesion disassembly and
cell de-adhesion from substratum (Xie et al., 1998), we
predicted this process is negatively modulated by IP-10
Figure 8. The effects of ELR-negative CXC chemokines on EGF-induced cell migration (a), EGF-induced calpain activation (b), and
PDGF-induced motility (c). (a) Cells were grown to confluence and quiesced for 48 h before treatment with or with out IP-10 (50 ng/
ml), MIG (100 ng/ml), PF4 (50 ng/ml), and/or EGF (1 nM). Cell migration assays were performed as described in Materials and Meth-
ods. The data are shown as the ratio to the 1 nM EGF-induced cell migrative activity. The data are the mean 6 SEM of at least three
independent studies each performed in triplicate. Statistical analyses were performed by Student’s t test as compared with EGF-induced
cell migrative capacity in the absence of CXC chemokines: **P , 0.01. (b) Cells were grown to confluence in 10-cm tissue culture plates
and quiesced for 48 h. Cells were treated with or without IP-10 (50 ng/ml), MIG (100 ng/ml), and/or PF4 (50 ng/ml) for 4 h before EGF
(1 nM) for 30 min. Calpain activities were analyzed by measuring the elevation in fluorescence intensity that occurs upon calpainolytic
digestion of dichlorotriazinylamino-fluorescein–labeled MAP2. The data are shown as a ratio to EGF-induced calpain activation. The
data are the mean 6 SEM of at least three independent studies. Statistical analyses were performed by Student’s t test as compared with
EGF-induced calpain activation in the absence of CXC chemokines: **P , 0.01. (c) Cells were grown to confluence and quiesced for
48 h before treatment with or without IP-10 (50 ng/ml), Rp-8-Br-cAMPS (50 mM), and/or PDGF-BB (5 ng/ml). Cell migration assays were
performed as described in Materials and Methods. The data are shown as the ratio to the 5 ng/ml PDGF-induced cell migrative activity.
The data are the mean 6 SEM of two independent studies each performed in triplicate. Statistical analyses were performed by Stu-
dent’s t test.Shiraha et al. IP-10 Inhibits Fibroblast Motility 251
treatment. 4-h treatment with IP-10 before EGF exposure
reduced the EGF-induced cell detachment by over half
(compared with IP-10 alone) in the centrifugation detach-
ment assay. Interestingly, IP-10 alone caused a small but
reproducible decrease in adhesiveness, though the pre-
dominant effect was to block the much greater EGF-
induced de-adhesion. Thus, IP-10 does not globally in-
crease adhesiveness to substratum but rather inhibits the
EGF-induced modulation of cell-substratum interactions
necessary for cell migration. This may be the basis for the
differential outcome of IP-10 limiting EGF-induced motil-
ity but having no discernible effect on basal, haptokinetic
motility.
IP-10 could limit EGFR-mediated detachment, and thus
motility, by either anchoring the adhesion sites or disrupt-
ing signaling pathways leading to de-adhesion. We did not
favor the former, as IP-10 has no discernible effect on
basal cell motility or morphometry; alterations in these as-
says due to inhibition of basal haptokinesis would be ex-
pected if IP-10 directly strengthened adhesive sites (Hut-
tenlocher et al., 1997; Palecek et al., 1997). Furthermore,
IP-10 alone diminished cell adhesiveness, albeit slightly.
Rather, we focused on signaling pathways downstream of
MEK by which EGFR signaling decreases cell-substratum
attachment (Xie et al., 1998). Calpain, which we have
shown to be activated by EGFR signaling in related stud-
ies (Glading, A., P. Chang, D.A. Lauffenburger, and A.
Wells, manuscript in preparation), has been implicated re-
cently in the control of cell-substratum interactions (Hut-
tenlocher et al., 1997; Stewart et al., 1998). Calpain local-
izes to focal adhesion and establishes associations with
focal adhesion components including integrin cytoplasmic
domains (Beckerle et al., 1987; Du et al., 1995; Cooray et
al., 1996; Inomata et al., 1996). A reduction in calpain ac-
tivity inhibits cell migration by decreasing the rate of cell
detachment and stabilizing integrin-cytoskeletal linkages
(Huttenlocher et al., 1997). To assess whether calpain acti-
vation may be the target of IP-10 signaling, we found that
IP-10 treatment inhibited z70% of EGF-induced calpain
activation. This inhibition is concordant with the inhibition
of EGF-induced de-adhesion and motility. Treating the
cells with a calpain inhibitor also resulted in EGF-induced
motility and de-adhesion being reduced similarly to IP-10
treatment. As an aside, as calpain has been implicated in
the formation of new adhesions and thus may be required
for stable adhesion to substratum, it may be expected that
negative regulation of calpain activity by IP-10 may lead to
lessened adhesiveness even in the absence of EGF. This is
what was noted by the centrifugation detachment assay.
The molecular bases of both the calpain activation by
EGFR signaling and its disruption by IP-10 receptor sig-
naling are unknown. As IP-10 has been reported to bind to
CXCR3 and elevate cAMP levels (Aronica et al., 1995;
Loetscher et al., 1996), we examined this possibility. IP-10
caused a slow rise in intracellular cAMP in human skin fi-
broblast Hs68, consistent with the previous report of he-
matopoietic cells (Aronica et al., 1995). The cell perme-
ant cAMP analogue, CPT-cAMP, inhibited EGF-induced
calpain activation almost completely. CPT-cAMP, dibu-
tyryl-cAMP, and forskolin also inhibited EGF-induced
cell migration similarly to IP-10. In addition, time lapse
videomicroscopy of the murine WT NR6 fibroblasts stim-
ulated to move by EGF clearly demonstrated significantly
decreased motility in the presence of CPT-cAMP while
showing that the presence of CPT-cAMP did not retard
forward extension but limited the detachment of the cell
tails; often cells were seen to recoil back to their original
position (data not shown). Thus, the biophysical behavior
of cells in the presence of increased cAMP mimicked that
of cells treated with IP-10. The cell permeable cAMP-
dependent PKA inhibitor Rp-8-Br-cAMPS, but not the
PKG preferential inhibitor Rp-8-Br-cGMPS, abrogated
IP-10’s inhibitory effect on cell migration, cell detachment,
and calpain activation. According to our results, IP-10
likely works by activating cAMP-dependent PKA. At this
point we have not eliminated the possibility that cAMP-
dependent PKA might also affect focal adhesions directly
through phosphorylation of paxillin (Han and Rubin, 1996)
or affect other components of the adhesion apparatus
(Brown et al., 1998). Thus, cAMP seems to be the opera-
tive second messenger for this IP-10 attenuation of EGFR
signaling. How cAMP and PKA prevent EGF-induced ac-
tivation of calpain is being explored. Initial data suggest
that IP-10 prevents an EGFR-mediated dissociation of
calpain from its endogenous inhibitor calpastatin (data not
shown). This is compelling as calpain II, the isoform im-
plicated as the target for EGF induction (Glading, A.,
P. Chang, D.A. Lauffenburger, and A. Wells, manuscript
in preparation), presents an evolutionarily conserved PKA
consensus site in domain III (Imajoh et al., 1988). How-
ever, several additional investigations, including molecular
abrogation of putative kinase sites, will be required to de-
termine the exact mechanism by which PKA attenuates
growth factor–induced calpain activation.
There appears to be a discrepancy between IP-10’s pre-
dominant inhibition of calpain activation and only partial
inhibition of cell motility and de-adhesion. This difference
may suggest that IP-10 inhibition of EGF-induced de-
adhesion and motility is independent of suppression of
calpain activation. However, this is unlikely, as exposure
of the cells to calpain inhibitor I presented a similar partial
inhibition of motility and de-adhesion. While we and oth-
ers have not yet determined the exact mechanism or pre-
cise molecular targets by which calpain modulates cell-
substratum adhesion (Huttenlocher et al., 1997; Byzova
and Plow, 1998; Stewart et al., 1998), these data strongly
link calpain functioning to cell adhesion. The quantitative
discrepancy between the extent of calpain inhibition and
limiting de-adhesion likely highlights a situation in which
calpain-mediated de-adhesion is only one of many modu-
lated events involved in cell migration. Abrogation of
calpain signaling in CHO cells did not completely prevent
rear detachment, and in fact, this effect was barely noted
on a substratum of low adhesiveness, suggesting that rear
detachment may be accomplished in absence of calpain ac-
tivation if the linkage with substratum is weak (Hutten-
locher et al., 1997). Huttenlocher et al. (1997) concluded
that rear detachment is one rate-limiting step in motility,
but calpain activity becomes a predominant rate-limiting
biochemical signal only when cells migrate over substrata
of high adhesiveness. We analyze motility and de-adhesion
on biologically complex matrices which contain both adhe-
sive and antiadhesive signals (Siegal et al., 1993; Ware et
al., 1998), and thus the Hs68 cells may be on substrata forThe Journal of Cell Biology, Volume 146, 1999 252
which rear detachment can occur, at least partly, in the ab-
sence of calpain activation. Additionally, IP-10 may modu-
late cell adhesiveness via pathways in addition to calpain
(Han and Rubin, 1996); in fact, IP-10 itself slightly de-
creases adhesiveness, though a similar small decrease in
adhesiveness is noted in the presence of calpain inhibitor I.
In summary, the extent of inhibition of calpain is consis-
tent with the observed lesser decrements in de-adhesion
and motility.
Two predictions derive from this model in which calpain
serves as a point of convergence for pro-motility signals
and their counterregulatory signals. The first is that other
extracellular signals that increase cAMP in a similar fash-
ion to IP-10 should also decrease EGF-induced motility.
We determined that the other ELR-negative CXC che-
mokines, MIG and PF4, also inhibited EGF-induced cell
migration. These chemokines induced cAMP generation
and inhibited EGF-induced calpain activation indistin-
guishably from IP-10. The second prediction is that these
chemokines should abrogate motility signaled by other
growth factors. Motility induced by another growth factor
present during wound healing, PDGF, was partially lim-
ited by IP-10. That these two postulates are supported by
experimental data strongly supports our model of IP-10
limiting growth factor–induced cell migration by inhibiting
calpain activation.
In summary, we have defined for the first time a regula-
tory crosstalk between counterstimulatory chemokines
and growth factor receptors. That this is specific for one
cellular response to a pleiotropic signal highlights the
closely orchestrated control of wound healing. One could
easily envision a function for IP-10 in this respect; IP-10
would limit cell infiltration late in the reparative phase
while leaving untouched other EGFR-mediated responses,
such as production of matrix components and remodeling
enzymes (Mawatari et al., 1989; Shima et al., 1993; Konda-
paka et al., 1997; van der Zee et al., 1998). Furthermore,
during the important phase of fibroblast-mediated wound
contraction, IP-10–signaled inhibition of calpain activation
would prevent breakdown of critical cell-matrix connec-
tions. A similar scenario could be invoked for MIG-medi-
ated inhibition of calpain activation, as this chemokine
also is generated late in wound healing (Engelhardt et al.,
1998). Seemingly, PF4 presents a different situation in that
is it released in large quantities from platelets during the
earliest stage of wounding. However, this may be critical
to appropriately targeting fibroblasts during wound heal-
ing. We have demonstrated that during chemokinesis in
response to growth factors, cell locomotive speed is in-
creased but persistence decreased so that dispersion is
maximized (Ware et al., 1998). Thus, speed is intrinsic to
the cell upon EGFR signaling, but localization would be
dictated by external signals. PF4 could be one such exter-
nal signal that limits motility as fibroblasts approach the
initial platelet plug. As fibroblasts migrate into the wound
site, they would accumulate nearest the platelet plug, but
still be able to proliferate and perform other functions to
replace the dermal tissue in response to the TGF-a and
HB-EGF from platelets and macrophages, as well as other
growth factors such as PDGF. As the wound healing
progresses, the PF4 would be consumed and the motility
block would be relieved with the fibroblasts then able to
migrate to appropriate positions for the reparative phase
of wound healing. While at present this is just one possible
explanation for the specific counterregulatory effects of
the ELR-negative CXC chemokines, it provides for a
working model to test these cell behaviors and signaling
pathways. Deciphering the precise molecular mechanisms
will not only provide insight into the complex network of
communications operational during organogenesis and re-
pair, but also suggest targets for rational intervention.
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